Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.53T
24h Vol:
$11.53B
Dominance:
MSFT:5.18%
Stocklytics Platform
BETA
Instrument logo  CBAY

Cymabay Therapeutics Inc

CBAY
50 / 100
$32.23arrow_drop_up0.12%$0.04

Performance History

Stocklytics logo
Key Stats
Open$32.23
Prev. Close$32.19
EPS-0.99
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.69B
PE Ratio-
LOWHIGH
Day Range32.19
32.35
52 Week Range7.26
32.35
Ratios
P/B Ratio12.65
Revenue$31.07M
Operating M. %-74,557.90%
Earnings$0.00
Earnings Growth %0.60%
EBITDA Margin %-325.03%
ROE %-64.17%
EPS-0.99

Score Breakdown

50vs 53. Market Avg.

All Score 50 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

CBAYMARKET
Value2439
Quality3440
Ownership019
Growth6846
Dividends-37
check_circle

Cymabay Therapeutics Inc's Price growth average in the last 3 years of 138% is great compared to market average of 7.44%. This indicates CBAY could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$782.12
24H (%)arrow_drop_up3.77%
24H ($)$28.44
MARKET CAP$743.14B
PRICE$489.53
24H (%)arrow_drop_down-0.82%
24H ($)-$4.07
MARKET CAP$452.77B
PRICE$162.12
24H (%)arrow_drop_up0.45%
24H ($)$0.73
MARKET CAP$390.50B
PRICE$126.96
24H (%)arrow_drop_down-0.14%
24H ($)-$0.19
MARKET CAP$321.54B

About Cymabay Therapeutics Inc (CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Sujal A. Shah
Headquarters
Newark
Employees
60
Exchange
NASDAQ
add Cymabay Therapeutics Inc to watchlist

Keep an eye on Cymabay Therapeutics Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Cymabay Therapeutics Inc's (CBAY) price per share?

The current price per share for Cymabay Therapeutics Inc (CBAY) is $32.23. The stock has seen a price change of $0.04 recently, indicating a 0.12% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Cymabay Therapeutics Inc (CBAY)?

For Cymabay Therapeutics Inc (CBAY), the 52-week high is $32.35, which is 0.37% from the current price. The 52-week low is $7.26, the current price is 343.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Cymabay Therapeutics Inc (CBAY) a growth stock?

Cymabay Therapeutics Inc (CBAY) has shown an average price growth of 138% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cymabay Therapeutics Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Cymabay Therapeutics Inc (CBAY) stock price performance year to date (YTD)?

As of the latest data, Cymabay Therapeutics Inc (CBAY) has a year-to-date price change of 35.99%. Over the past month, the stock has experienced a price change of 35.31%. Over the last three months, the change has been 58.3%. Over the past six months, the figure is 134.4%. Looking at a longer horizon, the five-year price change stands at 140.16%.

question_mark
Is Cymabay Therapeutics Inc (CBAY) a profitable company?

Cymabay Therapeutics Inc (CBAY) has a net income of -$105.37M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 100% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -74.56K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $31.07M, with a revenue growth rate of 0.18%, providing insight into the company's sales performance and growth. The gross profit is $31.07M. Operating income is noted at -$101.68M. Furthermore, the EBITDA is -$101M.

question_mark
What is the market capitalization of Cymabay Therapeutics Inc (CBAY)?

Cymabay Therapeutics Inc (CBAY) has a market capitalization of $3.7B. The average daily trading volume is 3.72M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.